
1. nanomedicine. 2016 aug;12(6):1489-98. doi: 10.1016/j.nano.2016.02.015. epub 2016 
mar 22.

inhibition hepatitis c virus mouse models lipidoid nanoparticle-mediated
systemic delivery sirna prk2.

moon js(1), lee sh(1), han sh(1), kim ej(1), cho h(1), lee w(1), kim mk(1), kim
te(1), park hj(1), rhee jk(2), kim sj(1), cho sw(1), han sh(3), oh jw(4).

author information: 
(1)department biotechnology, yonsei university, seoul, korea.
(2)western seoul center korea basic science institute, seoul, korea.
(3)department oral microbiology immunology, dental research institute,
school dentistry, seoul national university, seoul, korea.
(4)department biotechnology, yonsei university, seoul, korea. electronic
address: jwoh@yonsei.ac.kr.

host-targeting antivirals advantage direct-acting antivirals that
they high genetic barrier resistance. here, describe vivo
anti-hepatitis c virus (hcv) efficacy potent sirna targeting protein
kinase c-related kinase 2 (prk2), phosphorylates hcv ns5b rna-dependent rna
polymerase promotes hcv replication. prk2-silencing reduced the
phosphorylated ns5b level resulted inhibition ns5b rdrp activity to
decrease hcv genome abundance. systemic administration lipidoid
nanoparticle-formulated prk2 sirna (once every three days total three
injections dose 3mgkg(-1)) resulted 3.72 1.96 log10 reduction in
serum hcv rna titer, mouse subcutaneous orthotopic xenograft models for
hcv replication, respectively. results verify essential role prk2 in
hcv replication offer host-targeting anti-hcv sirna therapy might be
beneficial non-responders current treatment regimens.

copyright Â© 2016 elsevier inc. rights reserved.

doi: 10.1016/j.nano.2016.02.015 
pmid: 27013134  [indexed medline]

